1. Anti-infection Metabolic Enzyme/Protease
  2. SARS-CoV Virus Protease Ser/Thr Protease
  3. TMP1

TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM)/TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research.

For research use only. We do not sell to patients.

TMP1

TMP1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM)/TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research[1].

In Vitro

TMP1 (48 h) has no cytotoxicity against wild-type SARS-CoV-2 and other variants (VOCs), including Alpha, Beta, Delta, and Omicron (BA.1 and JN.1), in VeroE6-TMPRSS2 cells, reduced viral gene copy number and virus titer in human nasal epithelial cells (ALI-hNEC) infected with SARS-CoV-2 Omicron subtypes JN.1 and KP.2[1]. TMP1 (0-20 μM, 24 h) reduces both viral burden and infectious progeny viral titres in VeroE6, VeroE6-TMPRSS2, and LLC-MK2 cells were conducted in the presence of 2 µM P-gp inhibitor CP-100356 (HY-108347)[1].
TMP1 (0-50 μM, 24-48 h) inhibits the replication of seasonal HCoVs (HCoV-HKU1, -OC43, -NL63 and -229E) with EC50 ranging from 0.31 to 2.60 µM, cross-protects against highly-pathogenic coronaviruses SARS-CoV-1 and MERS-CoV with the EC50 of 0.55 and 5.26 µM[1].
TMP1 (1-50 μM) inhibits TMPRSS2-dependent cell-cell fusion mediated by the SARS-CoV-2 wild-type spike[1].
TMP1 inhibits recombinant the Mpro of SARS-CoV-2, SARS-CoV-1 and MERS-CoV, with IC50s of 0.313, 0.516 and 74.6 μM[1].
TMP1 (0-50 μM) reduces SARS-CoV-2, SARS-CoV-1, and MERS-CoV replication in TMPRSS-2-deficient VeroE6 cells[1].
TMP1 reduces the intracellular viral gene copies of rSARS-CoV-2 NSP5-E166V, resulting in EC50 of 0.449 μM in rSARS-CoV-2 NSP5-E166V infected Calu3 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TMP1 (100 mg/kg, o.p., twice per day, 4 days) reduces viral burdens in the infected mouse airways and ameliorates infection-associated tissue pathology, thus improving the overall survival of the infected SARS-CoV-2-infected heterozygous K18-hACE2 C57BL/6 J mice[1].
TMP1 (90 mg/kg, o.p., once) is against the prevalent Omicron lineage in the human upper airway epithelium and effectively attenuates SARS-CoV-2 transmission in PFU SARS-CoV-2 Delta-infected golden syrian hamsters model[1].
TMP1 (100-150 mg/kg, o.p., twice per day, 4 days) confers broad-spectrum antiviral protection against SARS-CoV-1-infected heterozygous mice and MERS-CoVMA-infected heterozygous hDPP4-KI mice[1].
TMP1 (100 mg/kg, o.p., twice per day, 4 days) interacts with Mpro using a distinct mechanism when compared with NRV, therefore retaining the sensitivity in rSARS-CoV-2 NSP5-E166V-infected heterozygous K18-hACE2 C57BL/6 J mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SARS-CoV-2-infected (500-1250 PFU) heterozygous K18-hACE2 C57BL/6 J mice (6-12-week-old)[1]
Dosage: 100 mg/kg
Administration: o.p., twice per day, 4 days
Result: Could be maintained at 11.1-, 11.4- and 6.5-fold higher than its in vitro EC50 of SARS-CoV-2 Delta. Suppressed SARS-CoV-2 infection, reduced viral burdens in the lung tissues, the expression of N protein, alleviated or absent loss of epithelium integrity, septal inflammation, alveoli deformation, and submucosal inflammatory infiltrations. Delayed onset of death, rescued the survival rate, lowered viral gene copies by 7.3- and 9.2-fold in the nasal turbinate and lung tissues, respectively.
Animal Model: SARS-CoV-2 Delta-infected 2000 PFU) golden syrian hamsters (8- to 10-week-old) model[1]
Dosage: 90  mg/kg
Administration: o.p., once
Result: Reduced viral gene copies in the exposed nasal canal, infectious virus titers, viral load in lung tissue, and viral N protein expression, alleviated the massive inflammatory infiltration in the alveolar septa and alveolar deformation.
Animal Model: SARS-CoV-1-infected (500 PFU) heterozygous K18-hACE2 C57BL/6 J mice (6-12-week-old)[1]
Dosage: 100 mg/kg
Administration: o.p., twice per day, 4 days
Result: Reduced viral load and SARS-CoV-1 nucleocapsid protein expression in nasal turbinates and lung tissues, titers of infectious viral progeny in the lungs, and alleviated loss of nasal mucosal epithelial integrity and alveolar damage.
Animal Model: MERS-CoVMA-infected (500 PFU) heterozygous hDPP4-KI C57BL/6 J mice (6-12-week-old)[1]
Dosage: 150 mg/kg
Administration: o.p., twice per day, 4 days
Result: Suppressed MERS-CoVMA replication in both nasal turbinates and lungs, decreased infectious viral titres and expression of MERS-CoVMA N protein in the nasal turbinate and lung tissues. Alleviated virus-induced epithelial damage in the nasal turbinate and reduced alveolar destruction.
Animal Model: RSARS-CoV-2 NSP5-E166V-infected heterozygous K18-hACE2 C57BL/6 J mice (6-12-week-old)[1]
Dosage: 100 mg/kg
Administration: o.p., twice per day, 4 days
Result: Reduced infectious virus titers in nasal turbinates and lung tissues, viral antigens in nasal turbinates, N protein expression in infected lung tissue samples, and ameliorated virus-induced pathological changes.
Molecular Weight

718.21

Formula

C36H43ClF3N5O5

SMILES

O=C(C([C@H](NC([C@@H]1C[C@H](CN1C([C@H](C2CCCCC2)NC(C3CCC(F)(CC3)F)=O)=O)F)=O)CC4=CC=CC=C4)=O)NCC5=NC=C(C=C5)Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TMP1
Cat. No.:
HY-175344
Quantity:
MCE Japan Authorized Agent: